Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Medicine Launching U.S. Business With Weight-Loss Supplement

This article was originally published in The Tan Sheet

Executive Summary

BEIJING - China Medicine Corp. is making its U.S. debut in one of the most competitive consumer product categories - dietary supplements for weight loss

You may also be interested in...

Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population

Bayer's antidiabetes drug Glucobay (acarbose), an alpha-glucosidase inhibitor, is already one of the company's strongest products in China.

New Vaccine Partnership With GSK Could Act As Lifeline For Chinese Biotech Firm Neptunus In Troubled Financial Seas

GlaxoSmithKline provides leading-edge vaccine technology and equipment, along with an injection of cash totaling almost $30 million, while Neptunus contributes its production facilities and access to the Chinese market.

Will Being On China’s New Essential Drugs List Be A Boon Or A Bane?

Pharma execs debate the issue while awaiting release of the pared-down list, now anticipated sometime in June.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts